ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

The biotech chose to add a second candidate in April when it inked a $1.8 billion deal to buy ProfoundBio for a rival to AbbVie’s Elahere. It had a third asset thrust into its hands in August ...

Here’s how it works. The best PS5 accessories can take your setup to new heights with boosted audio, more storage space, and extra charging options. Of course, between all the usual headsets and ...

Here’s how it works. The best PSVR 2 accessories are designed to help you enhance your virtual reality experience on PlayStation 5, or to provide various conveniences that’ll help make ...

It’s worth noting that BMS’ decision to exit the deal comes shortly after AbbVie secured full FDA approval for its FRα-directed ADC candidate – Elahere (mirvetuximab soravtansine ...

Ovarian cancer is a relatively manageable malignancy when diagnosed at an early stage, but late-stage detection almost always translates into a poor prognosis. Researchers have been vigorously ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Bonnie Qin, PhD, assistant professor at Rutgers Cancer institute, discusses factors that may influence adherence to dietary guidelines and improve survival for Black women with ovarian cancer.